NCT05505669 Circulating Biomarkers in the Development of Type 1 Diabetes
| NCT ID | NCT05505669 |
| Status | Recruiting |
| Phase | — |
| Sponsor | City of Hope Medical Center |
| Condition | Diabetes |
| Study Type | OBSERVATIONAL |
| Enrollment | 165 participants |
| Start Date | 2022-03-29 |
| Primary Completion | 2026-06-09 |
Trial Parameters
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
Brief Summary
More than 100 million U.S. adults are now living with diabetes or prediabetes. Investigators still do not fully understand how diabetes develops and how the disease worsens. Insulin is a hormone that helps the body use sugar as a fuel and control blood-sugar levels. People with diabetes have problems making insulin. This is because their insulin-producing beta cells -in the pancreas-are damaged or destroyed. A biomarker is a biological molecule (such as DNA, RNA (the genetic material of cells) or protein) that is a sign of a normal or abnormal process, or of a condition or disease. A biomarker can be measured and found in blood and/or other body fluids (such as saliva and urine). Understanding the biology of beta cells could help find diabetes-related biomarkers. The discoveries from this research could help with early diagnosis of diabetes and lead to the creation of therapies for treating diabetes.
Eligibility Criteria
Inclusion Criteria: * Documented informed consent/ assent from the subject * ONE of the following: * Type 1 diabetes patients (including pediatric patients) -OR- * Adult type 2 diabetes patients -OR- * Volunteers who are islet auto-antibody positive (i.e. insulin, GAA, IA-2, IAA and ZnT8 antibodies) with HbA1c ≤ 5.6% (including pediatric patients)-OR- * Adult participants with clinical diagnosis of high blood sugar (i.e. HbA1c of 5.7% to 6.4%)-OR- * Adult control subjects with HbA1cc ≤ 5.6% * Weight ≥ 30 kg * Willingness to: Provide blood sample(s) and if applicable: permit medical record/ clinical laboratory result review Exclusion Criteria: * Control subjects must not have any chronic conditions or have undergone cellular, tissue or organ transplant * Sickle cell disease or anemia (exception: anemia that is corrected with treatment and source documents confirm corrected blood parameters current within 6 months of blood draw) * Active infection * Active malignancy (i.e., currently und
Related Trials
Related Intelligence Guides
In-depth guides covering this condition's trials, eligibility, and what to expect.